News from lipocine inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 13, 2023, 14:45 ET Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that results of ...

Nov 08, 2023, 08:00 ET Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary...

Nov 01, 2023, 08:00 ET Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an...

Oct 26, 2023, 08:00 ET Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary...

Oct 23, 2023, 19:00 ET Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will...

Sep 19, 2023, 16:05 ET Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh ...

Aug 10, 2023, 08:00 ET Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial...

Jul 27, 2023, 06:30 ET LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary...

Jun 14, 2023, 08:00 ET Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary...

Jun 07, 2023, 08:00 ET Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary...

May 16, 2023, 07:00 ET Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone) with a...

May 11, 2023, 06:00 ET Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary...

Apr 03, 2023, 08:00 ET First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary...

Mar 10, 2023, 08:30 ET Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board ...

Mar 10, 2023, 08:30 ET Lipocine Announces Financial Results for the Year Ended December 31, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary...

Jan 05, 2023, 08:00 ET Lipocine to Present at Biotech Showcase

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary...

Dec 19, 2022, 08:00 ET Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary...

Nov 09, 2022, 08:00 ET Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its proprietary...

Nov 03, 2022, 08:00 ET Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop...

Oct 11, 2022, 08:00 ET Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products...

Sep 27, 2022, 13:21 ET Lipocine to Participate in the Cantor Neurology & Psychiatric Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products...

Sep 26, 2022, 08:00 ET Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products...

Sep 22, 2022, 16:10 ET Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment therapeutics through...

Sep 15, 2022, 08:00 ET Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products targeting large addressable markets with...

Aug 08, 2022, 08:00 ET Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system...